Display options
Cite
Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3(6):369-78doi: 10.1177/1756285610388343.
Eftekhari, S., & Edvinsson, L. (2010). Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Therapeutic advances in neurological disorders, 3(6), 369-78. https://doi.org/10.1177/1756285610388343
Eftekhari, Sajedeh, and Edvinsson, Lars. "Possible sites of action of the new calcitonin gene-related peptide receptor antagonists." Therapeutic advances in neurological disorders vol. 3,6 (2010): 369-78. doi: https://doi.org/10.1177/1756285610388343
Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010 Nov;3(6):369-78. doi: 10.1177/1756285610388343. PMID: 21179597; PMCID: PMC3002638.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Neurol Disord. 2010 Nov;3(6):369-78. doi: 10.1177/1756285610388343.

Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.

Therapeutic advances in neurological disorders

Sajedeh Eftekhari, Lars Edvinsson

Affiliations

  1. Department of Clinical Sciences, Division of Experimental Vascular Research, BMC A13, Sölvegatan 17, SE-22184 Lund, Sweden.

PMID: 21179597 PMCID: PMC3002638 DOI: 10.1177/1756285610388343

Abstract

Migraine is considered a neurovascular disease affecting more than 10% of the general population. Currently available drugs for the acute treatment of migraine are vasoconstrictors, which have limitations in their therapeutic use. The calcitonin gene-related peptide (CGRP) has a key role in migraine, where levels of CGRP are increased during acute migraine attacks. CGRP is expressed throughout the central and peripheral nervous system, consistent with control of vasodilatation and transmission of nociceptive information. In migraine, CGRP is released from the trigeminal system. At peripheral synapses CGRP results in vasodilatation via receptors on the smooth muscle cells. At central synapses, CGRP acts postjunctionally on second-order neurons to transmit pain centrally via the brainstem and midbrain to higher cortical pain regions. The recently developed CGRP-receptor antagonists have demonstrated clinical efficacy in the treatment of acute migraine attacks. A remaining question is their site of action. The CGRP-receptor components (calcitonin receptor-like receptor, receptor activity modifying protein 1 and receptor component protein) are found to colocalize in the smooth muscle cells of intracranial arteries and in large-sized neurons in the trigeminal ganglion. The CGRP receptor has also been localized within parts of the brain and the brainstem. The aim of this paper is to review recent localization studies of CGRP and its receptor components within the nervous system and to discuss whether these sites could be possible targets for the CGRP-receptor antagonists.

Keywords: brainstem; calcitonin gene-related peptide; calcitonin gene-related peptide antagonists; migraine; trigeminal ganglion

References

  1. Eur J Pharmacol. 2006 Jan 13;530(1-2):107-16 - PubMed
  2. J Biol Chem. 2000 Oct 6;275(40):31438-43 - PubMed
  3. J Cereb Blood Flow Metab. 1999 Nov;19(11):1270-8 - PubMed
  4. Brain Res Mol Brain Res. 2001 Sep 10;93(1):36-45 - PubMed
  5. Neurology. 2009 Sep 22;73(12):970-7 - PubMed
  6. J Intern Med. 1990 Oct;228(4):299-304 - PubMed
  7. Cephalalgia. 2002 Jul;22(6):424-31 - PubMed
  8. Headache. 2007 Jul-Aug;47(7):1008-23; discussion 24-5 - PubMed
  9. Neurosci Lett. 1985 Jul 31;58(2):213-7 - PubMed
  10. Lancet. 2008 Dec 20;372(9656):2115-23 - PubMed
  11. Neuroscience. 2009 Sep 1;162(3):545-8 - PubMed
  12. Neurology. 1993 Jun;43(6 Suppl 3):S16-20 - PubMed
  13. Headache. 2007 Jun;47(6):820-33 - PubMed
  14. Ann Neurol. 1990 Aug;28(2):183-7 - PubMed
  15. Ann N Y Acad Sci. 1992 Jun 30;657:119-34 - PubMed
  16. J Neurocytol. 1999 Jun;28(6):431-8 - PubMed
  17. Cephalalgia. 2009 Sep;29(9):935-48 - PubMed
  18. Trends Pharmacol Sci. 2007 Nov;28(11):580-7 - PubMed
  19. Brain Res. 2001 Aug 3;909(1-2):112-20 - PubMed
  20. J Cereb Blood Flow Metab. 2002 May;22(5):620-9 - PubMed
  21. Eur J Neurosci. 2001 Aug;14(4):618-28 - PubMed
  22. Ann Neurol. 1993 Jan;33(1):48-56 - PubMed
  23. Neuroscience. 2010 Aug 25;169(2):683-96 - PubMed
  24. Nature. 1998 May 28;393(6683):333-9 - PubMed
  25. Brain Res. 2008 Feb 27;1196:22-32 - PubMed
  26. Neurosci Lett. 2005 Jun 10-17;381(1-2):120-4 - PubMed
  27. Neurosci Lett. 1997 Jul 4;229(3):209-11 - PubMed
  28. J Neurosci. 1984 Dec;4(12):3101-11 - PubMed
  29. Headache. 2006 Jun;46 Suppl 1:S3-8 - PubMed
  30. Headache. 2006 Jan;46(1):24-33 - PubMed
  31. Headache. 1997 Nov-Dec;37(10):622-5 - PubMed
  32. N Engl J Med. 2004 Mar 11;350(11):1104-10 - PubMed
  33. Regul Pept. 1988 Mar;20(3):181-97 - PubMed
  34. Lancet. 2001 Mar 31;357(9261):1016-7 - PubMed
  35. Brain Res Brain Res Rev. 2005 Jun;48(3):457-76 - PubMed
  36. Trends Mol Med. 2007 Jan;13(1):39-44 - PubMed
  37. Neuroscience. 1985 Jul;15(3):747-63 - PubMed
  38. J Headache Pain. 2010 Dec;11(6):485-95 - PubMed
  39. Lancet. 1979 Oct 27;2(8148):883-5 - PubMed
  40. J Pharmacol Exp Ther. 2010 Sep 1;334(3):746-52 - PubMed
  41. Neurosci Lett. 1998 Dec 11;258(1):41-4 - PubMed
  42. Lancet. 2008 Dec 20;372(9656):2089-90 - PubMed
  43. Eur J Neurosci. 2008 Dec;28(11):2213-20 - PubMed
  44. Neurotherapeutics. 2010 Apr;7(2):164-75 - PubMed
  45. J Cereb Blood Flow Metab. 1999 Feb;19(2):115-27 - PubMed
  46. Ann Neurol. 1988 Feb;23(2):193-6 - PubMed
  47. Mol Pain. 2009 Aug 06;5:43 - PubMed
  48. Circ Res. 1993 Sep;73(3):579-88 - PubMed
  49. Cephalalgia. 2010 Oct;30(10):1233-40 - PubMed
  50. Peptides. 1998;19(7):1213-25 - PubMed
  51. J Chem Neuroanat. 1991 Jul-Aug;4(4):299-309 - PubMed
  52. Pharmacol Ther. 1992;56(1):23-51 - PubMed
  53. Peptides. 1985 Jul-Aug;6(4):721-45 - PubMed
  54. J Cardiovasc Pharmacol. 2010 May;55(5):518-21 - PubMed
  55. J Cereb Blood Flow Metab. 1987 Dec;7(6):720-8 - PubMed
  56. Neuroscience. 2001;108(4):655-71 - PubMed
  57. Nat Med. 1995 Jul;1(7):658-60 - PubMed
  58. Pharmacol Rev. 2008 Jun;60(2):143-5 - PubMed
  59. Trends Pharmacol Sci. 1999 May;20(5):184-7 - PubMed
  60. Neuroscience. 2000;100(2):381-91 - PubMed
  61. Peptides. 2001 Jun;22(6):995-1007 - PubMed
  62. J Auton Nerv Syst. 1999 May 28;76(2-3):176-83 - PubMed
  63. Neurotherapeutics. 2007 Apr;4(2):274-84 - PubMed
  64. J Comp Neurol. 2005 Sep 26;490(3):239-55 - PubMed
  65. J Neurosci. 2007 Mar 7;27(10):2693-703 - PubMed
  66. Nat Rev Neurol. 2010 Oct;6(10):573-82 - PubMed
  67. Neuroreport. 1998 Nov 16;9(16):3755-9 - PubMed
  68. Neurosci Lett. 2010 Apr 12;473(3):163-7 - PubMed
  69. Neurochem Int. 1988;12(3):323-35 - PubMed
  70. J Pharmacol Exp Ther. 2009 Feb;328(2):571-8 - PubMed
  71. Lancet. 2010 Aug 21;376(9741):645-55 - PubMed
  72. Eur J Pharmacol. 2009 Nov 25;623(1-3):96-102 - PubMed
  73. Brain Res. 1989 Dec 18;504(2):315-9 - PubMed
  74. Brain Behav Immun. 2007 Jul;21(5):592-8 - PubMed
  75. Brain Res. 1986 May 28;374(2):287-98 - PubMed
  76. Neuropeptides. 2001 Feb;35(1):58-64 - PubMed
  77. Cerebellum. 2009 Sep;8(3):260-6 - PubMed
  78. Cephalalgia. 2008 Dec;28(12):1245-58 - PubMed
  79. J Comp Neurol. 2008 Mar 20;507(3):1277-99 - PubMed
  80. Br Med Bull. 2005 Oct 05;73-74:83-92 - PubMed
  81. Mol Cell Neurosci. 2011 Jan;46(1):333-9 - PubMed
  82. Neurology. 2008 Apr 15;70(16):1304-12 - PubMed
  83. Brain Res. 2004 Jan 30;997(1):97-102 - PubMed

Publication Types